Hoth Therapeutics Inc., is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Eczema is a disease that results in inflammation of the skin and is characterized by rash, red skin, and itchiness. Eczema is also referred to as atopic dermatitis. According to the National Eczema Association, this chronic skin condition affects approximately 32 million Americans and, at $300 per annum per patient, represents a $9.5 billion market in the U.S. alone.

Hoth is the exclusive sublicensee of the BioLexa platform, a proprietary, patented, drug compound platform for the treatment of eczema which was developed at the University of Cincinnati. The Biolexa platform combines an FDA approved zinc chelator with one or more approved antibiotics in a topical dosage form to address the un-checked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts which trigger symptoms. It is the first product candidate intended to prevent the symptom triggering flare-ups rather than simply treating symptoms when they occur. Biolexa has achieved positive results in its initial studies conducted at the University of Miami.